Michelle Boyer

Statistics

Publications

Citations

2.9K

H-Index

Active since

1976

Affiliations

Roche (United Kingdom)(Current)

AbbVie (United States)

Peter MacCallum Cancer Centre

The Royal Melbourne Hospital

The University of Melbourne

Michelle Boyer is an author at Roche (United Kingdom) specializing in chronic lymphocytic leukemia therapy, medicine, and refractory chronic lymphocytic leukemia.

Publications per year

1976–2025

Publications

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq et al. · The Lancet Infectious Diseases · 2017 · 577 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +12

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Arnon P. Kater, John F. Seymour, Peter Hillmen et al. · Journal of Clinical Oncology · 2018 · 301 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater, Jenny Wu, Thomas J. Kipps et al. · Journal of Clinical Oncology · 2020 · 220 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2022 · 151 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

1–5 of 26